

PERSONAL INFORMATION Aranzazu Sancho-Lopez**WORK EXPERIENCE**

October 2018–Present **Medical Staff Clinical Pharmacology Department**
Hospital Universitario Puerta de Hierro Majadahonda (Spain)
Local drug policy
Pharmacovigilance

June 2017–Present **Medical Staff Clinical Pharmacology Department**
Research Institute Hospital Universitario Puerta de Hierro (Spain)
Support to local drug policy, support to academia research.
External assessor (AEMPS)

March 2011–May 2017 **CHMP alternate member**
AEMPS/ Research Institute Hospital Puerta de Hierro, Madrid (Spain)
Spanish Medicines and Medical devices Agency, AEMPS
Centralised Procedures Unit
Alternate Member CHMP
Responsible for supervision and representation at CHMP of the Spanish Agency position on procedures involving medicinal products throughout the centralised procedure.

December 2005–January 2011 **Medical Staff**
Research Institute University Hospital Puerta de Hierro, Madrid Majadahonda (Spain)
Responsible for the Clinical Research Support Unit,
External Clinical Assessor for the AEMPS

EDUCATION AND TRAINING

November 2015–November 2018 **Philosophical Degree in clinical Pharmacology**
Universidad Autonoma Barcelona (Spain)
New clinical trials designs and methods of analysis for small populations

July 2002–November 2005 **Clinical assessor**
AEMPS (Spain)

May 1998–June 2002 **Internal Medical Resident**
Hospital La Paz (Spain)
Medical Internal Resident in Clinical Pharmacology with formation in Internal Medicine (hospitalization, emergency department), Clinical trials Unit, drug monitoring, drug-interactions, drug information, etc
Specialist in Clinical Pharmacology throughout the MIR procedure (official procedure).

ADDITIONAL INFORMATION

Expertise
Oncology
Reumatology
Neurology

, Dermatology

Publications

IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY

Ana Fernandez-Cruz, Belen Ruiz-Antoran, Ana Munoz-Gomez, Aranzazu Sancho-Lopez, Patricia Mills-Sanchez, Gustavo Adolfo Centeno-Soto, Silvia Blanco-Alonso, Laura Javaloyes-Garachana, Amy Galan-Gomez, Angela Valencia-Alijo, Javier Gomez-Irusta, Concepcion Payares-Herrera, Ignacio Morras-Torre, Enrique Sanchez-Chica, Laura Delgado-Tellez-de-Cepeda, Alejandro Callejas-Diaz, Antonio Ramos-Martinez, Elena Munez-Rubio, Cristina Avendano-Sola

medRxiv 2020.05.22.20110544; doi: <https://doi.org/10.1101/2020.05.22.20110544>

Belén Ruiz-Antoran†, Aranzazu Sancho-López†, et al. A randomized placebo controlled clinical trial to evaluate the efficacy and safety of minocycline in patients with Angelman syndrome (A-MANECE study) Orphanet Journal of Rare Diseases 201813:144

<https://doi.org/10.1186/s13023-018-0891-6>

Caridad Pontes at al. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties

Orphanet Journal of Rare Diseases 201813:206

<https://doi.org/10.1186/s13023-018-0926-z>

Marian Mitroi†, Katrien Oude Rengerink†, at al. Applicability and added value of novel methods to improve drug development in rare diseases. Orphanet Journal of Rare Diseases 201813:200

<https://doi.org/10.1186/s13023-018-0925-0>

Marijke C. at al. Rare Disease Registries: potential applications towards impact on

development of new drug treatments . Orphanet Journal of Rare Diseases (2018) 13:154

<https://doi.org/10.1186/s13023-018-0836-0>

K.TZOGANI, et al. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. The Oncologist 2017;22:1339–1346

A. Sancho(1,2), E. González (3), J. Camarero(1). Emerging Therapies in Metastatic Castration-Resistant Prostate Cancer: A Regulatory Perspective. Global Journal of Oncologist, 2013, 1, 13-19 13

Zahra Hanaizi, Christoph Unkring, Harald Enzmann, Jorge Camarero, Arantxa Sancho-Lopez, tomas Salmonson, et al. The European medicines Agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukaemia: summary of the scientific assessment fo the CHMP. The oncologist.

Jordanis Gravanis, Arantxa Sancho López, et al. The European meidicnes Agency review of abirterone for the treatment of metastatic castration resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naïve disease: summary of the scientific assessment of the CHMP. The European oncologist.

Arantxa Sancho, Daniela Melchiorri, Eric Abadie. Letter to the editor: More on influenza Vaccine in Young Children. N Engl J Med 366; 26 June 28, 2012.

Hanaizi Z, Van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E, Pignatti F. The European medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer. 2012 Jan; 48 (2): 237-42. Epub 2011 Oct 24.

† Isabel Salcedo de Diego, Belén Ruiz Antorán, Arantxa Sancho López, Lourdes Cabrera García. Notificación de sospecha de reacciones adversas a medicamentos mediante la tarjeta amarilla. Metas de Enfermería. Dic 2009/ene 2010; 12(10): 24-29.

† Cabrera García L., Ruiz Antorán, B., Sancho López, A. Eritropoyetina: revisión de sus indicaciones. Información Terapéutica del Sistema Nacional de Salud, 2009; 33 (1), 3-9.

Projects

Investigator in the project: Advances in Small Trials dEsign for Regulatory Innovation and eXcellence: ASTERIX.

Collaborative Project (small-scale focused research project)

Work programme topics addressed: HEALTH.2013.4.2-3: New methodologies for clinical trials for small population groups. FP7-HEALTH-2013-INNOVATION-1

Name of the coordinating person, University name, country: Prof. dr. Kit C.B. Roes, UMC Utrecht, the Netherlands

Memberships

Alternate Member HCPWP, representing EACPT

Member of the Rheumatology Working Party (RIWP) (2011- 2018)

Member of the Guideline Consistency Group (GCG) (January 2016- to date)

Observer at Respiratory Drafting Group (2011-2014)

Alternate Member at EWP (2006-10)

Member of the CNS drafting group: 2006-2010

Representative of the EWP at the cell-therapy group: 2006-2007

Co/Rapporteur for the following guidelines: Psoriatic Arthritis, Ankylosing Spondylitis, Multiple Sclerosis, COPD, Lupus, Asthma.

Member of the add-oc group for the use of preservatives in Eye Drop Formulations (2009).

Member of the Research Ethics Committee at Hospital Jiménez Díaz, Madrid (2005-April 2017).

Member of the Executive Committee of the EACPT, Secretary EACPT (June 2017-to date)

Other Relevant Information